- Home
- FTDR vs SRRK Comparison
FTDR vs SRRK Comparison
Compare FTDR & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTDR
- SRRK
- Stock Information
- Founded
- FTDR 1971
- SRRK 2012
- Country
- FTDR United States
- SRRK United States
- Employees
- FTDR N/A
- SRRK N/A
- Industry
- FTDR Diversified Commercial Services
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FTDR Finance
- SRRK Health Care
- Exchange
- FTDR Nasdaq
- SRRK Nasdaq
- Market Cap
- FTDR 4.3B
- SRRK 3.2B
- IPO Year
- FTDR 2018
- SRRK 2018
- Fundamental
- Price
- FTDR $57.32
- SRRK $38.87
- Analyst Decision
- FTDR Hold
- SRRK Strong Buy
- Analyst Count
- FTDR 4
- SRRK 6
- Target Price
- FTDR $54.00
- SRRK $42.17
- AVG Volume (30 Days)
- FTDR 594.5K
- SRRK 1.4M
- Earning Date
- FTDR 08-05-2025
- SRRK 08-07-2025
- Dividend Yield
- FTDR N/A
- SRRK N/A
- EPS Growth
- FTDR 34.69
- SRRK N/A
- EPS
- FTDR 3.08
- SRRK N/A
- Revenue
- FTDR $1,891,000,000.00
- SRRK N/A
- Revenue This Year
- FTDR $12.86
- SRRK N/A
- Revenue Next Year
- FTDR $6.54
- SRRK $502.60
- P/E Ratio
- FTDR $18.68
- SRRK N/A
- Revenue Growth
- FTDR 5.58
- SRRK N/A
- 52 Week Low
- FTDR $34.60
- SRRK $6.76
- 52 Week High
- FTDR $63.49
- SRRK $46.98
- Technical
- Relative Strength Index (RSI)
- FTDR 49.79
- SRRK 62.99
- Support Level
- FTDR $57.17
- SRRK $36.91
- Resistance Level
- FTDR $59.06
- SRRK $38.15
- Average True Range (ATR)
- FTDR 1.47
- SRRK 1.85
- MACD
- FTDR -0.36
- SRRK 0.29
- Stochastic Oscillator
- FTDR 40.77
- SRRK 92.45
About FTDR Frontdoor Inc.
Frontdoor Inc is a United States-based company that provides home service plans. It owns multiple home service brands including American Home Shield, HSA, OneGuard, and Landmark brands. Through its home service plans, the company helps its customers maintain their homes and protect against costly and unexpected breakdowns of essential home systems and appliances.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.